Wide Ranks

BHVN

Biohaven Ltd.

46.38

Top Statistics
Market Cap 4 B Forward PE -7.83 Revenue Growth 0.00 %
Current Ratio 2.89 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.15 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 378 M Total Cash Per Share 3.75 Total Debt 25 M
Total Debt To Equity 8.01 Current Ratio 2.89 Book Value Per Share 3.33
All Measures
Short Ratio 1030.00 % Message Board Id finmb_1796230042 Shares Short Prior Month 9 M
Return On Equity -2.65 City New Haven Uuid 2bb7b4da-cd98-31f5-9833-032448a765e9
Previous Close 47.28 First Trade Date Epoch Utc 1 B Book Value 3.33
Total Debt 25 M Volume 569774 Price To Book 13.93
Fifty Two Week Low 26.80 Total Cash Per Share 3.75 Shares Short Previous Month Date 1 B
Target Median Price 63.50 Max Age 86400 Recommendation Mean 1.33
Sand P52 Week Change 0.3133 Target Mean Price 65.07 Net Income To Common -804334976
Ask 46.49 Short Percent Of Float 0.0869 Implied Shares Outstanding 101 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 968330
Average Volume10days 968330 Total Cash 378 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1116 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 47.28 Target Low Price 56.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 49.54 Open 47.10
Free Cashflow -397263872 State CT Dividend Yield 0.00 %
Return On Assets -1.19 Time Zone Short Name EST Trailing Eps -9.37
Day Low 46.17 Address1 215 Church Street Shares Outstanding 101 M
Price Hint 2 Target High Price 77.00 Website https://www.biohaven.com
52 Week Change 0.3920 Average Volume 1 M Forward Eps -6.32
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 252.20 %
Is_sp_500 False Regular Market Day High 47.75 Profit Margins 0.00 %
Debt To Equity 8.01 Fifty Two Week High 62.21 Day High 47.75
Shares Short 7 M Regular Market Open 47.10 Industry Key biotechnology
Bid 46.01 Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0774 Operating Cashflow -526592000 Currency USD
Time Zone Full Name America/New_York Market Cap 4 B Is_nasdaq_100 False
Zip 06510 Quote Type EQUITY Industry Biotechnology
Long Name Biohaven Ltd. Regular Market Day Low 46.17 Held Percent Institutions 0.8677
Current Price 46.38 Enterprise To Ebitda -5.15 Financial Currency USD
Current Ratio 2.89 Industry Disp Biotechnology Number Of Analyst Opinions 14
Country United States Float Shares 84 M Two Hundred Day Average 43.71
Enterprise Value 4 B Forward PE -7.83 Regular Market Volume 569774
Ebitda -841603008 Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Biohaven Ltd.

, together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.

The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.

In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma.

It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co.

Ltd.

The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd.

in September 2022.

Biohaven Ltd.

was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd.

was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.